| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥1734.7B | ¥1711.7B | +1.3% |
| Operating Income | ¥318.3B | ¥357.6B | -11.0% |
| Ordinary Income | ¥345.2B | ¥376.1B | -8.2% |
| Net Income | ¥256.1B | ¥276.8B | -7.5% |
| ROE | 9.0% | 9.9% | - |
FY2026 Q3 results: Revenue 173.5B yen (YoY +1.3%), Operating Income 31.8B yen (YoY -11.0%), Ordinary Income 34.5B yen (YoY -8.2%), Net Income 25.6B yen (YoY -7.5%). The company faces a revenue up/profit down scenario with top-line growth limited to 1.3% while operating profitability contracted significantly. Gross profit margin of 35.9% remains solid, but SG&A expenses of 30.4B yen compressed operating margin to 18.3% from prior year levels. Non-operating income of 3.2B yen and extraordinary gains of 1.8B yen from investment securities sales partially offset operating profit decline. Full-year guidance anticipates recovery with revenue of 260.5B yen (+9.3%) and operating income of 46.0B yen (+1.5%), implying substantial second-half acceleration.
Revenue grew modestly by 1.3% to 173.5B yen, driven by mixed segment performance. Functional Chemicals segment recorded revenue of 110.6B yen (down 6.9B yen YoY), representing 63.7% of consolidated revenue and serving as the core business. Pharmaceuticals, Medicals and Health segment maintained stable revenue of 37.3B yen (down 0.5B yen YoY). Explosive and Propulsion segment revenue increased significantly to 29.6B yen (up 9.9B yen or +50.1% YoY), providing primary growth momentum. Operating income declined 11.0% to 31.8B yen, with operating margin contracting 2.4 percentage points to 18.3% from 20.9% prior year. The profit decline stemmed from segment-level margin compression, particularly in Functional Chemicals where operating income fell to 20.2B yen (down 4.4B yen YoY) despite its scale. SG&A expenses increased to 30.4B yen (ratio 17.5%), contributing to margin pressure. Ordinary income of 34.5B yen exceeded operating income by 2.7B yen, attributed to non-operating income including dividend income of 1.1B yen, foreign exchange gains of 0.7B yen, and other non-operating income totaling 3.2B yen. The gap between ordinary income (34.5B yen) and net income (25.6B yen) of 8.9B yen reflects income tax expense of 10.6B yen and non-recurring gains from investment securities sales of 1.8B yen. This represents a revenue up/profit down pattern, where modest top-line expansion failed to translate into operating leverage due to cost structure pressures and segment mix deterioration.
Functional Chemicals generated revenue of 110.6B yen and operating income of 20.2B yen with margin of 18.3%, constituting the core business at 63.7% of total revenue. However, this segment experienced the largest profit decline with operating income down 4.4B yen YoY, indicating competitive or cost pressures. Pharmaceuticals, Medicals and Health produced revenue of 37.3B yen and operating income of 10.7B yen with the highest margin at 28.7%, maintaining relatively stable performance with operating income down 1.0B yen YoY. Explosive and Propulsion delivered revenue of 29.6B yen and operating income of 2.8B yen with margin of 9.6%, showing the strongest revenue growth at +50.1% YoY and operating income improvement of 1.3B yen. The material margin differential between segments (28.7% for Pharmaceuticals versus 9.6% for Explosive) highlights portfolio mix impact on consolidated profitability. The decline in the highest-margin Functional Chemicals segment represents the primary driver of overall margin compression.
[Profitability] ROE 9.0% positions above industry median of 5.8% but reflects decline from operating profit contraction; operating margin 18.3% substantially exceeds industry median of 8.9% indicating strong structural profitability; net profit margin 14.8% significantly outperforms industry median of 6.5%. [Cash Quality] Cash and deposits 75.6B yen provides substantial liquidity; short-term debt coverage 51.7x indicates minimal refinancing risk; working capital cycle extends to 276 days (receivables 124 days, inventory 230 days, payables 77 days), substantially exceeding industry median working capital turnover of 112 days and flagging material efficiency concerns; inventory turnover of 112 days aligns with industry median of 112 days but masks underlying accumulation in finished goods and work-in-process. [Investment Efficiency] Asset turnover 0.46 trails industry median of 0.56, indicating suboptimal asset utilization; return on assets 6.8% exceeds industry median of 3.4%; return on invested capital 8.5% surpasses industry median of 6.0%. [Financial Health] Equity ratio 75.6% substantially exceeds industry median of 63.8%, demonstrating conservative capitalization; current ratio 306.1% far above industry median of 287%; debt-to-equity ratio 0.01 reflects minimal leverage with interest-bearing debt of only 3.3B yen; financial leverage 1.32 below industry median of 1.53 indicates underutilization of capital structure for returns.
Cash and deposits increased 20.5B yen YoY to 75.6B yen, reflecting continued cash accumulation despite profit decline. Operating profit generation contributed to the cash position, though working capital efficiency deteriorated significantly. Receivables expanded to 58.7B yen (up 7.3B yen YoY) with collection period extending to 124 days, substantially above industry median of 85 days. Inventory increased to 34.3B yen (up 5.9B yen YoY) with finished goods, raw materials, and work-in-process all rising, resulting in inventory days of 112 aligning with industry median but representing accumulation risk. Payables of 23.4B yen provide payment terms of 77 days, above industry median of 56 days but insufficient to offset extended cash cycle. The cash conversion cycle of 276 days significantly exceeds industry norm of 112 days, indicating capital trapped in operations. Investment securities position of 49.3B yen reflects strategic holdings, with realized gains of 1.8B yen during the period. Treasury stock increased dramatically to 21.3B yen (up 15.0B yen), signaling aggressive share repurchase activity. The company maintains strong liquidity coverage with cash representing 51.7x short-term debt and 10.7% of total assets, though working capital management requires improvement to enhance cash generation quality.
Ordinary income of 34.5B yen versus operating income of 31.8B yen shows net non-operating contribution of approximately 2.7B yen, comprising primarily interest and dividend income of 1.4B yen, foreign exchange gains of 0.7B yen, and other non-operating income of 1.0B yen. Non-operating income represents 1.8% of revenue, indicating limited dependency. Extraordinary items included gains on sale of investment securities of 1.8B yen, representing non-recurring factors that enhanced reported profit by 7.0% of net income. The gap between ordinary income (34.5B yen) and net income (25.6B yen) of 8.9B yen reflects effective tax rate of 29.3%, consistent with statutory rates. Comprehensive income of 30.6B yen exceeded net income by 5.0B yen, driven by unrealized gains on investment securities of 5.6B yen, partially offset by foreign currency translation adjustments of negative 0.4B yen and remeasurements of defined benefit plans of negative 0.3B yen. The significant unrealized securities gains indicate potential future realization opportunities but also mark-to-market volatility risk. Operating cash flow quality cannot be fully assessed due to quarterly statement limitations, but working capital deterioration (extended receivables and inventory accumulation) suggests cash conversion below reported earnings, indicating earnings quality concerns despite strong profitability metrics.
Full-year guidance projects revenue of 260.5B yen (YoY +9.3%), operating income of 46.0B yen (+1.5%), and ordinary income of 49.5B yen (+6.3%). Q3 progress rates stand at 66.6% for revenue and 69.2% for operating income against full-year targets. With three quarters complete representing 75% of the fiscal year, revenue tracking 8.4 percentage points below standard pace while operating income runs 5.8 points below, indicating modest underperformance requiring fourth quarter acceleration. The guidance implies Q4 revenue of 87.0B yen (+21.3% QoQ) and operating income of 14.2B yen, representing significant sequential improvement from Q3 run-rate. Management assumptions center on recovery in Functional Chemicals segment and sustained momentum in Explosive and Propulsion business. The operating income guidance growth of only 1.5% despite revenue growth of 9.3% signals anticipated margin compression of 1.3 percentage points to 17.7% for the full year, consistent with observed Q3 trends. EPS forecast of 171.21 yen implies full-year net income of 39.4B yen, with Q3 representing 64.9% progress, also below standard 75% threshold. The forecast implies payout ratio of 20.4% based on annual dividend of 35.00 yen, maintaining conservative distribution policy with substantial retained earnings for reinvestment.
Annual dividend forecast of 35.00 yen consists of interim dividend of 21.00 yen and year-end dividend of 24.00 yen, though historical comparison data is not available in current disclosure. Based on forecasted EPS of 171.21 yen, payout ratio stands at 20.4%, providing substantial coverage and reinvestment capacity. Against Q3 actual EPS of 110.81 yen, the annual dividend represents 31.6% payout, still within sustainable range. Treasury stock increased dramatically by 15.0B yen during the nine-month period to 21.3B yen, indicating active share repurchase program representing significant capital allocation alongside dividends. With net income of 25.6B yen for nine months and estimated dividend payments of approximately 8.1B yen (35 yen times 231 million shares outstanding), combined with share buybacks of 15.0B yen, the total shareholder return approaches 23.1B yen or 90% of nine-month net income, demonstrating aggressive capital return policy. The total return ratio significantly exceeds the dividend payout ratio alone, reflecting management's commitment to shareholder value through dual mechanisms. The sustainability of this combined return level depends on working capital efficiency improvement and maintenance of operating cash generation, particularly given the observed deterioration in cash conversion cycle.
Working capital efficiency deterioration represents the primary risk, with cash conversion cycle extending to 276 days (2.5x industry median of 112 days), driven by receivables collection period of 124 days (45% above industry median of 85 days) and inventory accumulation with days inventory outstanding of 230 days. The 34.3B yen inventory position increased 20.6% YoY with finished goods, raw materials, and work-in-process all expanding, creating obsolescence risk and capital tie-up that constrains free cash flow generation. Segment concentration and margin pressure in Functional Chemicals business, representing 63.7% of revenue, poses structural profitability risk as this core segment experienced operating income decline of 4.4B yen (17.9%) YoY with margin compressing to 18.3%. Recovery of this segment is critical to achieving full-year guidance but faces uncertain demand or competitive dynamics. Aggressive capital allocation with combined dividends and share buybacks approaching 90% of nine-month net income creates sustainability concerns if operating cash generation weakens further due to working capital demands, particularly given guidance for only 1.5% operating income growth despite 9.3% revenue expansion indicating continued margin pressure. The reliance on non-recurring gains from investment securities sales of 1.8B yen (7.0% of net income) to support reported profitability introduces earnings quality risk if such gains cannot be repeated.
[Industry Position] (Reference - Proprietary Analysis) Profitability: ROE 9.0% substantially exceeds industry median of 5.8% (2025-Q3, n=105), placing the company in the upper performance tier; Operating Margin 18.3% significantly outperforms industry median of 8.9%, demonstrating superior pricing power or cost efficiency; Net Profit Margin 14.8% more than doubles industry median of 6.5%, indicating strong bottom-line conversion despite recent margin compression. Financial Health: Equity Ratio 75.6% exceeds industry median of 63.8%, reflecting conservative capital structure with minimal leverage; Current Ratio 306.1% surpasses industry median of 287%, confirming strong liquidity position; Net Debt/EBITDA of negative 16.9 compares favorably to industry median of negative 1.11, indicating net cash position far exceeding peers. Efficiency: Asset Turnover 0.46 trails industry median of 0.56, suggesting room for improvement in asset utilization despite strong profitability; Operating Working Capital Turnover of 276 days substantially exceeds industry median of 112 days, representing the most significant relative weakness and flagging urgent need for receivables and inventory management improvement; Receivables Turnover 124 days extends 45% beyond industry median of 85 days, indicating collection challenges. Growth: Revenue Growth 1.3% YoY trails industry median of 2.8%, positioning below peers in top-line momentum; EPS Growth of negative 4.6% underperforms industry median of positive 9.0%, reflecting profit margin compression despite revenue growth. Returns: Return on Assets 6.8% doubles industry median of 3.4%, demonstrating effective profit generation from asset base; Return on Invested Capital 8.5% exceeds industry median of 6.0%, though financial leverage of 1.32 below median of 1.53 indicates potential for enhanced returns through optimization of capital structure. (Industry: Manufacturing (n=105), Comparison: 2025-Q3, Source: Proprietary analysis)
Structural profitability advantage with operating margin of 18.3% and net margin of 14.8% both exceeding industry medians by wide margins (operating margin 2.1x industry, net margin 2.3x industry) demonstrates competitive positioning and pricing power that provides foundation for value creation despite recent margin compression. The company maintains this profitability superiority even as absolute margins declined 2.4 percentage points YoY in operating margin, suggesting structural advantages rather than transient factors. Critical working capital efficiency gap represents the most significant operational challenge, with cash conversion cycle of 276 days at 2.5x industry median exposing 164 days of excess capital tied in operations. Receivables collection of 124 days (45% above industry median) and combined with inventory accumulation of 34.3B yen (up 20.6% YoY) creates approximately 30-40B yen of trapped capital that could otherwise fund growth investments or shareholder returns. Management's guidance for 9.3% revenue growth but only 1.5% operating income growth explicitly signals anticipated full-year margin compression to 17.7%, indicating pricing or cost pressures that warrant monitoring for persistence versus cyclical factors. Aggressive capital return policy with total shareholder returns (dividends plus 15.0B yen share buybacks) approaching 90% of nine-month earnings demonstrates commitment to value distribution, yet sustainability depends on operating cash flow improvement given working capital headwinds. The company's net cash position of 72.3B yen (cash 75.6B yen less debt 3.3B yen) and equity ratio of 75.6% provide financial flexibility to maintain distributions, but continued working capital deterioration could pressure this capacity. Segment diversification shows both opportunity and risk, with Explosive and Propulsion delivering 50% revenue growth and Pharmaceuticals maintaining 28.7% margins, while core Functional Chemicals (63.7% of revenue) experiencing profit decline of 4.4B yen requires strategic attention to stabilize consolidated performance.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.